<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

T. Shaw, Alice; Solomon, Benjamin; Besse, Benjamin; M. Bauer, Todd; Lin, Chia‐Chi; A. Soo, Ross; J. Riely, Gregory; Ignatius Ou, Sai‐Hong; S. Clancy, Jill; Li, Sherry; Abbattista, Antonello; Thurm, Holger; Satouchi, Miyako; Ross Camidge, D.; Kao, Steven; Chiari, Rita; M. Gadgeel, Shirish; Felip, Enriqueta; Martini, Jean‐François

doi:10.1200/jco.18.02236

Public

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Published in Journal of Clinical Oncology • Mar 20, 2019

Authors:

Alice T. Shaw

Benjamin Solomon

Benjamin Besse

Abstract

PURPOSE Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non–small-cell lung cancer, including in patients who have failed prior ALK TKIs. Molecular determinants of r...

Subject

Crizotinib

Anaplastic lymphoma kinase

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!